{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:54:15Z","timestamp":1792518855637,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drudis.2026.104722","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:20:52Z","timestamp":1781652052000},"page":"104722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integration of multi-omics for precision therapy in breast cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Pai-Sheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Liang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chih","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104722_b0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","article-title":"Cancer treatments: past, present, and future","volume":"286\u2013287","author":"Sonkin","year":"2024","journal-title":"Cancer Genet"},{"key":"10.1016\/j.drudis.2026.104722_b0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104722_b0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","article-title":"Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy","volume":"183","author":"Krug","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104722_b0020","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104722_b0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104722_b0030","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104722_b0035","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104722_b0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104722_b0045","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA approval summary: datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer","volume":"31","author":"Royce","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-025-00868-y","article-title":"Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling","volume":"12","author":"Sledge","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2026.104722_b0060","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","article-title":"Cancer cell plasticity during tumor progression, metastasis and response to therapy","volume":"4","author":"Perez-Gonzalez","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","article-title":"Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression","volume":"125","author":"Luond","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu1521","article-title":"Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer","volume":"11","author":"Mo","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104722_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108059","article-title":"Metabolic stratification of human breast tumors reveal subtypes of clinical and therapeutic relevance","volume":"26","author":"Iqbal","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2026.104722_b0080","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1200\/JCO.2007.15.5986","article-title":"Prognostic significance of Nottingham histologic grade in invasive breast carcinoma","volume":"26","author":"Rakha","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104722_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1016\/j.drudis.2026.104722_b0090","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104722_b0095","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104722_b0100","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104722_b0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van \u2018t Veer","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104722_b0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104722_b0115","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","article-title":"Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer","volume":"23","author":"Zhao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.csbj.2025.01.011","article-title":"Identifying somatic driver mutations in cancer with a language model of the human genome","volume":"27","author":"Zeng","year":"2025","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.drudis.2026.104722_b0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41592-021-01164-w","article-title":"Genome-wide detection of enhancer-hijacking events from chromatin interaction data in rearranged genomes","volume":"18","author":"Wang","year":"2021","journal-title":"Nat Methods"},{"key":"10.1016\/j.drudis.2026.104722_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117313","article-title":"DNA methylation as an oncogenic driver in breast cancer: therapeutic targeting via epigenetic reprogramming of DNA methyltransferases","volume":"242","author":"Kundu","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2026.104722_b0135","article-title":"P16 methylation increases the sensitivity of cancer cells to the CDK4\/6 inhibitor palbociclib","volume":"14","author":"Li","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104722_b0140","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/biom15081067","article-title":"Spatial transcriptomics decodes breast cancer microenvironment heterogeneity: from multidimensional dynamic profiling to precision therapy blueprint construction","volume":"15","author":"Ma","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104722_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1499301","article-title":"Spatial transcriptomics in breast cancer: providing insight into tumor heterogeneity and promoting individualized therapy","volume":"15","author":"An","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104722_b0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semcancer.2025.12.009","article-title":"Spatial multi-omics in precision medicine: integrating biological insights through multidisciplinary collaboration","volume":"119","author":"Kim","year":"2026","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104722_b0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.drudis.2026.104722_b0160","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104722_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2026.104722_b0170","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104722_b0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","article-title":"Identification of new immune target and signaling for cancer immunotherapy","volume":"294\u2013295","author":"Narote","year":"2025","journal-title":"Cancer Genet"},{"key":"10.1016\/j.drudis.2026.104722_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112808","article-title":"Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures","volume":"28","author":"Mebane","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2026.104722_b0185","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41576-025-00892-5","article-title":"Spatial architecture of development and disease","volume":"27","author":"Lazar","year":"2026","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.drudis.2026.104722_b0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41416-024-02917-y","article-title":"Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer","volume":"132","author":"Wang","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0195","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41467-023-36560-7","article-title":"Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis","volume":"14","author":"Xun","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104722_b0200","first-page":"851","article-title":"Clinical management of circulating tumor DNA in breast cancer: detection, prediction, and monitoring","volume":"17","author":"Lu","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.drudis.2026.104722_b0205","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104722_b0210","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13058-016-0788-z","article-title":"Circulating cell-free DNA-based epigenetic assay can detect early breast cancer","volume":"18","author":"Uehiro","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0215","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.ccell.2025.09.006","article-title":"Cell-free DNA fragmentomics in cancer","volume":"43","author":"Tsui","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104722_b0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104722_b0225","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-19-0622","article-title":"Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation","volume":"10","author":"Jiang","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104722_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104296","article-title":"Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay","volume":"10","author":"Janni","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.drudis.2026.104722_b0235","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.trecan.2021.06.001","article-title":"Technical and biological constraints on ctDNA-based genotyping","volume":"7","author":"Herberts","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13058-025-02024-7","article-title":"Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care","volume":"27","author":"Zhong","year":"2025","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0245","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.cell.2024.05.039","article-title":"Pan-cancer proteogenomics expands the landscape of therapeutic targets","volume":"187","author":"Savage","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104722_b0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-024-00648-0","article-title":"Gedatolisib shows superior potency and efficacy versus single-node PI3K\/AKT\/mTOR inhibitors in breast cancer models","volume":"10","author":"Rossetti","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0255","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13046-022-02330-4","article-title":"Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer","volume":"41","author":"Montero","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0260","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s44321-024-00090-6","article-title":"FADS1\/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer","volume":"16","author":"Lorito","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2026.104722_b0265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104722_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102006","article-title":"Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence","volume":"43","author":"Luis","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.drudis.2026.104722_b0275","first-page":"826","article-title":"Sulfasalazine\u2011induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor","volume":"42","author":"Yu","year":"2019","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2026.104722_b0280","first-page":"789","article-title":"Lactate and lactylation in breast cancer: current understanding and therapeutic opportunities","volume":"22","author":"Huang","year":"2025","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.drudis.2026.104722_b0285","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174587","article-title":"The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer","volume":"134","author":"Ju","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104722_b0290","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.cell.2024.04.002","article-title":"Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis","volume":"187","author":"Zong","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104722_b0295","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/0008-5472.CAN-23-3513","article-title":"H3K18 lactylation potentiates immune escape of non-small cell lung cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0300","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s43856-025-00930-7","article-title":"Development and multicenter validation of on-site breast cancer diagnosis using paper spray ionization miniature mass spectrometry","volume":"5","author":"Huang","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.drudis.2026.104722_b0305","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/acs.analchem.4c06062","article-title":"Untargeted swab touch spray-mass spectrometry analysis with machine learning for on-site breast surgical margin assessment","volume":"97","author":"Chai","year":"2025","journal-title":"Anal Chem"},{"key":"10.1016\/j.drudis.2026.104722_b0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13058-017-0845-2","article-title":"Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery","volume":"19","author":"St John","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0315","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1535-7163.MCT-16-0219","article-title":"Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers","volume":"15","author":"Chang","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104722_b0320","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-025-02094-7","article-title":"Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis","volume":"27","author":"Sledge","year":"2025","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.drudis.2026.104722_b0325","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0330","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104722_b0335","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.drudis.2026.104722_b0340","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41416-025-03174-3","article-title":"Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer","volume":"133","author":"Steggall","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104722_b0345","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.3390\/cancers16152635","article-title":"Depicting biomarkers for HER2-inhibitor resistance: implication for therapy in HER2-positive breast cancer","volume":"16","author":"Cai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104722_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drudis.2026.104722_b0355","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41592-024-02201-0","article-title":"scGPT: toward building a foundation model for single-cell multi-omics using generative AI","volume":"21","author":"Cui","year":"2024","journal-title":"Nat Methods"},{"key":"10.1016\/j.drudis.2026.104722_b0360","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-025-08710-y","article-title":"Towards multimodal foundation models in molecular cell biology","volume":"640","author":"Cui","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104722_b0365","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13040-024-00414-9","article-title":"Open challenges and opportunities in federated foundation models towards biomedical healthcare","volume":"18","author":"Li","year":"2025","journal-title":"Biodata Min"},{"key":"10.1016\/j.drudis.2026.104722_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105171","article-title":"Digital twins in oncology: from predictive modelling to personalised treatment strategies","volume":"220","author":"Olawade","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drudis.2026.104722_b0375","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41746-025-01579-1","article-title":"MRI-based digital twins to improve treatment response of breast cancer by optimizing neoadjuvant chemotherapy regimens","volume":"8","author":"Wu","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.drudis.2026.104722_b0380","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2589-7500(23)00044-4","article-title":"Augmenting digital twins with federated learning in medicine","volume":"5","author":"Nagaraj","year":"2023","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.drudis.2026.104722_b0385","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/1354750X.2025.2591717","article-title":"Emerging biomarkers in breast cancer: translational and multi-omics perspectives in precision oncology","volume":"30","author":"Yasmin","year":"2025","journal-title":"Biomarkers"},{"key":"10.1016\/j.drudis.2026.104722_b0390","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/pgs.13.142","article-title":"Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual","volume":"14","author":"Doble","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drudis.2026.104722_b0395","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00038-019-01298-x","article-title":"Cost-effectiveness of precision medicine: a scoping review","volume":"64","author":"Kasztura","year":"2019","journal-title":"Int J Public Health"},{"key":"10.1016\/j.drudis.2026.104722_b0400","article-title":"Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers","volume":"6","author":"Jaehnig","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2026.104722_b0405","article-title":"Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures","volume":"6","author":"Peyraud","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2026.104722_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101642","article-title":"Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?","volume":"8","author":"Aldea","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.drudis.2026.104722_b0415","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergen.2025.08.010","article-title":"Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration","volume":"298\u2013299","author":"Ubaid","year":"2025","journal-title":"Cancer Genet"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:44:06Z","timestamp":1789505046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1359644626001273"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104722","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integration of multi-omics for precision therapy in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104722"}}